An optimized dosing regimen of cimaglermin (neuregulin 1β3, glial growth factor 2) enhances molecular markers of neuroplasticity and functional recovery after permanent ischemic stroke in rats

Cimaglermin (neuregulin 1β3, glial growth factor 2) is a neuregulin growth factor family member in clinical development for chronic heart failure. Previously, in a permanent middle cerebral artery occlusion (pMCAO) rat stroke model, systemic cimaglermin treatment initiated up to 7 days after ischemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Iaci, Jennifer F., Parry, Tom J., Huang, Zhihong, Pavlopoulos, Elias, Finklestein, Seth P., Ren, Jingmei, Caggiano, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737294/
https://www.ncbi.nlm.nih.gov/pubmed/26660233
http://dx.doi.org/10.1002/jnr.23699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737294/
https://www.ncbi.nlm.nih.gov/pubmed/26660233
http://dx.doi.org/10.1002/jnr.23699

Ejemplares similares